Search Results 261-270 of 15179 for TNF

1. Nutrition and healthy eating Nutrition basics - Mayo Clinic

   You can master healthy eating by learning how to plan meals and shop smart, and by practicing healthy-cooking techniques.

2. Execute _Preview Minutes_ on HM00000252

   As a reminder to the lab, eye protection must be worn whenever there is the possibility of a spill or splash. All samples considered biosafety level 2/2+ ...

3. Early Fluconazole Treatment for Coccidiodomycosis Pneumonia - Mayo Clinic

   ... TNF medications, or other parenterally-administered immunomodulating agents; History of a solid organ or bone marrow transplant. Have poorly controlled HIV ...

4. A Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and Combined with Chemotherapy or Tislelizumab to Treat Patients with Metastatic Solid Tumors - Mayo Clinic

   ... tumor necrosis factor (anti-TNF) agents. Patients who have received or are receiving acute, low dose systemic immunosuppressant medications (e.g., ≤ 10 mg ...

5. Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa - Mayo Clinic

   Received any anti-TNF-α/other biologics treatment within 12 weeks or 5 elimination half‑lives, whichever is longer, before the Baseline Visit. Received ...

6. Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer - Mayo Clinic

   ... tumor necrosis factor [anti-TNF] agents) within 4 weeks prior to cycle 1, day 1; exceptions: (1) patients may have received acute, low dose, systemic ...

7. Neurology - Clinical trials - Mayo Clinic

   [MUSIC PLAYING]. Joseph Sirven, M.D., Professor of Neurology, Mayo Clinic: Mayo's mission is about the patient. The patient comes first.

8. A Study to Evaluate the Effectiveness and Safety of TD-1473 in Crohn's Disease - Mayo Clinic

   ... TNF anti-IL-12/IL-23 therapy, or anti-integrin). If subject is currently receiving an oral corticosteroid, subject is eligible if: the subject has been on ...

9. Statins for the Treatment of NASH - Mayo Clinic

   Immune modulatory agents including systemic steroids, methotrexate, anti-TNF-? therapies (infliximab, adalimumab, etanercept) or anti-integrin therapy

10. A Study To Evaluate Efficacy And Safety Of Tulisokibart (MK-7240) In Participants With Moderately To Severely Active Ulcerative Colitis (MK-7240-001) - Mayo Clinic

    An anti-TNF agent;; An anti-integrin (eg, vedolizumab);; A JAK inhibitor (eg, tofacitinib, upadacitinib, or filgotinib);; An anti-IL-23 or anti-IL-12/23 for UC ...